| 生物活性 |
Beta-Sitosterol (purity>98%) is orally active and exhibits anti-inflammatory, anticancer, antioxidant, antibacterial, antidiabetic, antioxidant enzyme, and analgesic activities; it inhibits inflammation and impaired lipogenesis in bovine mammary epithelial cells by reducing ROS, TNF-α, IL-1β, and NF-κB p65 levels and restoring HIF-1α/mTOR signaling pathway activity, induces cancer cell apoptosis through ROS-mediated mitochondrial dysfunction and p53 activation, exerts anticancer effects in cancer cells by activating caspase-3, caspase-8, and caspase-9, mediating PARP inactivation, MMP loss, alteration of the Bcl-2-Bax ratio, and cytochrome c release, modulates macrophage polarization and alleviates rheumatoid inflammation in mice, inhibits tumor growth in various mouse cancer models, and can be used for research on arthritis, lung cancer, breast cancer, and other cancers, as well as diabetes. |
体外研究 (In Vitro) |
Beta-Sitosterol (0-40 µM,24 小时) 浓度超过 5 µM 时,会降低 MAC-T 细胞的细胞活力。
Beta-Sitosterol (1 µM,24 小时) 可提高 LPS (MS-X54539) 诱导的 MAC-T 细胞中 CAT、GSH、T-AOC、T-SOD 的水平,并降低 ROS、TNF-α、IL-1β、NF-κB p65 的水平。
Beta-Sitosterol (1 µM,24 小时) 可抑制 LPS 诱导的 MAC-T 细胞凋亡,降低 caspase-3 和 Bax 的表达水平,提高 Bcl-2 和 Bcl-2/Bax 比值的水平。
Beta-Sitosterol (1 µM, 24 小时) 可恢复 LPS 诱导的 MAC-T 细胞中 HIF-1α/mTOR 信号通路活力和脂肪合成相关基因 (SCD、PSMA5、FASN、SREBP1) 的表达水平。
Beta-Sitosterol (25-200 µM,24-72 小时) 影响 A549 细胞的生长,72 小时时的 IC50 为 24.7 μM,增加 A549 细胞中 LDH 的释放,影响 NCI-H460 细胞的活力,但不影响正常人肺、PBMC 细胞和 NCI-H23 细胞的生长和活力。
Beta-Sitosterol (25-200 µM,24-72 小时) 在 A549 细胞中诱导细胞周期停滞于 Sub-G1 期,降低 Cyclin D1 和 CDK2 的表达水平。
Beta-Sitosterol (25-200 µM,0-72 小时) 通过线粒体功能障碍和 ROS 介导的 DNA 损伤诱导 A549 细胞凋亡。
Beta-Sitosterol (25-200 µM,0-72 小时) 可提高 A549 细胞中 caspase-3、caspase-9、PARP、Bax、p53 和 pSer15-p53 的表达水平,抑制 Bcl-2 的表达水平。
Beta-Sitosterol (25-200 µM,72 小时) 通过激活 NCI-H460 细胞中的 p53 诱导细胞凋亡。
Beta-Sitosterol 可降低 A549 和 NCI-H460 细胞中 TrxR1 和 Trx1 的表达。
Beta-Sitosterol (5-50 µM,24 小时) 可阻断 IFN-γ/IL-4 刺激的 BMBM 中的 M1 型巨噬细胞极化,但促进 M2 型巨噬细胞极化。
Beta-Sitosterol (1-150 μM/L,5 天) 可促进 MCF-7 细胞增殖。
Beta-Sitosterol (8-16 μM,5 天) 在 MCF-7 和 MDA-MB-231 细胞中可显著降低细胞生长,并改变细胞膜组成。
Beta-Sitosterol (16 μM,1-3 天) 可提高 MCF-7 和 MDA-MB-231 细胞中的 caspase-8 活性和 Fas 蛋白水平。
Beta-Sitosterol (0.1-100 μM,18 小时) 在 TNF-α 刺激的 HAEC 中可降低 VCAM-1 和 ICAM-1 表达,减弱 NFkB p65 的磷酸化,抑制 U937 细胞与 TNF-α 刺激的 HAEC 的结合。
Beta-Sitosterol (50 μM,1-6 小时) 可逆转 PMA (MS-C34076) 在 RAW 264.7 细胞中诱导的 GSSG 水平升高和 GSH 水平或 GSH/总谷胱甘肽比率降低。
Beta-Sitosterol (50 μM,1-6 小时) 可提高 RAW 264.7 细胞中的 GPx 和 Mn SOD 活性,并降低过氧化氢酶活性。
Cell Viability Assay
| Cell Line: |
MAC-T cells |
| Concentration: |
0, 0.01, 0.1, 1, 5, 10, 20, 30, and 40 µM |
| Incubation Time: |
24 h |
| Result: |
Decreased cell viability with concentrations exceeding 5 µM. |
Immunofluorescence
| Cell Line: |
LPS (1 µg/mL)-induced MAC-T cells |
| Concentration: |
1 µM |
| Incubation Time: |
24 h |
| Result: |
Decreased the level of DCFH-DA. |
RT-PCR
| Cell Line: |
LPS (1 µg/mL)-induced MAC-T cells |
| Concentration: |
1 µM |
| Incubation Time: |
24 h |
| Result: |
Slowed the mRNA expression levels of pro-inflammatory factors TNF-α and IL-1β down.
Upregulated the mRNA levels of HIF-1α and mTOR.
Restored the mRNA expression of fatty acid synthase (FASN) and sterol regulatory element-binding protein 1 (SREBP1) to the controls.
|
Western Blot Analysis
| Cell Line: |
LPS (1 µg/mL)-induced MAC-T cells |
| Concentration: |
1 µM |
| Incubation Time: |
24 h |
| Result: |
Attenuated NF-κB p65 production by LPS-induced and restored it to the same level as the control group.
Upregulated the protein expression of HIF-1α and the ratio of p-mTOR/mTOR.
Restored the protein expression of stearoyl coenzyme A dehydrogenase (SCD), proteasome 20 s subunit α5 (PSMA5) to the controls.
|
Apoptosis Analysis
| Cell Line: |
LPS (1 µg/mL)-induced MAC-T cells |
| Concentration: |
1 µM |
| Incubation Time: |
24 h |
| Result: |
Inhibited the apoptosis caused by LPS, attenuated the expression levels of mRNA and protein of caspase-3 and pro-apoptotic protein B-cell lymphoma-2-associated X protein (Bax), increased the protein levels of Bcl-2 and Bcl-2/Bax radio. |
Cell Cycle Analysis
| Cell Line: |
A549 cells |
| Concentration: |
25, 50, 100, 200 µM |
| Incubation Time: |
24, 48 and 72 h |
| Result: |
Affected the growth of cells in a concentration and time diferent manner. |
Immunofluorescence
| Cell Line: |
A549 cells |
| Concentration: |
25, 50, 100, 200 µM |
| Incubation Time: |
72 h |
| Result: |
Increased the number of PI positive cells. |
Cell Cycle Analysis
| Cell Line: |
A549 cells |
| Concentration: |
25, 50, 100, 200 µM |
| Incubation Time: |
24, 48, 72 h |
| Result: |
Induced cell cycle arrest at Sub-G1 phase in a time dependent, reduced the expression of both Cyclin D1 and CDK2. |
Apoptosis
| Cell Line: |
A549 cells |
| Concentration: |
25, 50, 100, 200 µM |
| Incubation Time: |
0, 1, 6, 24, 48, 72 h |
| Result: |
Increased early apoptotic cells and few late apoptotic cells upon 25μM exposure, elevated the protein expression levels of caspase-3, caspase-9, cleavage PARP.
Induced a concentration dependent disruption of ΔΨm afer 72h treatment, induced the release of cytochrome c into the cell cytoplasm in a dose dependent manner, suppressed the Bcl-2 and strongly increased the expression of Bax in a dose dependent manner.
Induced generation of DCF fuorescence at 6h of BS treatment and peaked at 12-48h time point, decreased at 72 h, caused severe DSBs and elevation of tail and olive movement, caused chromatin condensation and morphological alteration.
Up-regulated the protein expression of p53 and pSer15-p53.
|
Apoptosis Analysis
| Cell Line: |
NCI-H460 cells |
| Concentration: |
25, 50, 100, 200 µM |
| Incubation Time: |
72 h |
| Result: |
Induced cell shrinkage, elongation and reduced cell populations, elevated the protein expression levels of caspase-3, caspase-9, cleavage PARP.
Reduced the expression of Bcl-2 protein and signifcant elevated Bax and cytochrome c, up-regulated p53, pSer15-p53 and p21 expression.
|
RT-PCR
| Cell Line: |
BMDMs |
| Concentration: |
5, 25, 50 µM + 10 ng/mL IFN-γ/IL-4 |
| Incubation Time: |
24 h |
| Result: |
Decreased NOS and IL-1β to 50.2% and 47.1% at 25 μM in the presence of IFN-γ, and increased the expression of arginase-1 by approximately 0.5-fold and IL-10 by approximately 1-fold in the presence of IL-4, compared with vehicle-treated BMDMs. |
ELISA Assay
| Cell Line: |
HAECs |
| Concentration: |
0.1, 1, 10, 50, 100 µM + TNF-α (1 ng/mL), 24 h |
...(内容过长已截断)
体内研究 (In Vivo) |
Beta-Sitosterol (20-50 mg/kg,腹腔注射,每 2 天 1 次,共 31 天;2×106 个 BMDM 用 25 μM BS 静脉注射,一次) 在 Collagen (MS-B45528) 诱导的关节炎 (CIA) 小鼠模型通过抑制体液和细胞免疫反应以及部分通过 IL-10 转移来抑制病理变化。
Beta-Sitosterol (2-5 mg/20 g小鼠,腹腔注射,一次) 在 Acetic acid (MS-H89626) 诱导的瑞士韦伯斯特白化小鼠模型中起镇痛作用。
Beta-Sitosterol (2 mg/20 g小鼠,腹腔注射,一次) 在 Carrageenan (MS-L60716) 诱发的小鼠爪水肿模型中起抗炎作用。
Beta-Sitosterol (9.8 g/kg 饮食,口服,18 周) 可抑制植入 MCF-7 肿瘤的卵巢切除无胸腺小鼠雌激素反应性乳腺癌细胞的生长。
Beta-Sitosterol (10-20 mg/kg,口服,每日一次,21 天) 在 Streptozotocin (MS-Q80520) 诱发的糖尿病 Wistar 大鼠模型中具有抗糖尿病和抗氧化作用。
| Animal Model: |
CIA mice (six-week-old male C57BL/6) model |
| Dosage: |
20, 50 mg/kg + 30 μg LPS, i.p., on day 3 |
| Administration: |
i.p., every 2 days, 31 days |
| Result: |
Suppressed hind paw swelling and the production of collagen-specific IgG and IgG1, but not IgG2c.
Decreased IL-1β, IL-6, and IL-12 levels and increased IL-10 levels.
|
| Animal Model: |
CIA mice (six-week-old male C57BL/6) model |
| Dosage: |
2 × 106 BMDMs treating with 25 μM BS + 30 μg LPS, i.p., on day 3 |
| Administration: |
i.v., once |
| Result: |
Reduced ankle swelling and synovial inflammation, reduced serum collagen-specific IgG, IgG1, and IgG2a antibodies, as well as IL-1β and IL-6, and increased serum IL-10 levels. |
| Animal Model: |
Acetic acid-induced (0.7%, 0.2 mL/20 g mouse, i.p.) Swiss Webster albino mice (20-25 g) model |
| Dosage: |
2, 5 mg/20 g mouse |
| Administration: |
i.p., once |
| Result: |
Reduced peristalsis by 70%, exhibited a 300% increase in pain tolerance. |
| Animal Model: |
Carrageenan-induced mouse paw oedema model |
| Dosage: |
2 mg/20 g mouse |
| Administration: |
i.p., once |
| Result: |
Changed paw oedema volume by 16.7%. |
| Animal Model: |
MCF-7 tumors implanted (1 × 105, 40 μL) ovariectomized athymic nude mice (female athymic BALB/c) model |
| Dosage: |
9.8 g/kg diet |
| Administration: |
o.p., 18 weeks |
| Result: |
Did not affect tumor growth, regressed tumors after removal of the E2 pellet at wk 7, reduced 1:47 E2-induced tumor growth by 38.9%.
Downregulated Bcl-2 expression in the 1:47 E2 group by 38%, lowered the serum E2 level in the 1:47 E2 group by 35.1%.
|
| Animal Model: |
Streptozotocin-induced (i.p., 50 mg/kg) diabetes male albino Wistar rats (170-190 g) model |
| Dosage: |
10, 15, 20 mg/kg |
| Administration: |
o.p., once a day, 21 days |
| Result: |
Reduced blood glucose (37.5%, 45.2%, and 50.4% in diabetic rats) and NO (16.4%, 28.4%, and 47.1% in diabetic rats).
Prevented the induction of diabetes by 77.8% and 100% at 10, 15 mg/kg, increased insulin levels and lowered HbA1c levels, dose-dependent increased pancreatic protein content.
Improved antioxidant activity and significantly reduced LPO levels, caused the pancreatic cells to rejuvenate.
|
|
| 性状 |
固体 |
| 颜色 |
White to off-white |
| 分子量 |
414.71 |
| 分子式 |
C29H50O |
| CAS No. |
83-46-5 |
| 别名 |
β-谷甾醇 (purity>98%); β-Sitosterol (purity>98%); 22,23-Dihydrostigmasterol (purity>98%) |
| 储存方式 |
-20°C, protect from light
|
| 运输条件 |
Room temperature in continental US; may vary elsewhere. |
|
溶液配制表
|
Ethanol 中的溶解度 : 5 mg/mL (12.06 mM; 超声助溶 (<60°C)) | 可选溶剂 | 浓度 | 1 mg | 5 mg | 10 mg | 25 mg |
|---|
| Ethanol | 1 mM | 2.4113 mL | 12.0566 mL | 24.1132 mL | 60.2831 mL | | 5 mM | 0.4823 mL | 2.4113 mL | 4.8226 mL | 12.0566 mL | | 10 mM | 0.2411 mL | 1.2057 mL | 2.4113 mL | 6.0283 mL |
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。
该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。
|
动物实验计算换算器
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。
-
客服
2851296953
18923798467
微信洽谈
|